RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Botanix Pharmaceuticals Stock

Botanix Pharmaceuticals Stocks 2024

Botanix Pharmaceuticals Stocks

1.5 B

Ticker

BOT.AX

ISIN

AU000000BOT2

WKN

A2ANJ5

In 2024, Botanix Pharmaceuticals had 1.5 B outstanding stocks, a 30.12% change from the 1.15 B stocks in the previous year.

The Botanix Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
2027e1.5
2026e1.5
2025e1.5
20241.5
20231.15
20220.97
20210.97
20200.94
20190.76
20180.49
20170.43
20160.41
20150.08
20140.04
20130.01
20120
20110
20100
20090
20080
20070
20060
20050

Botanix Pharmaceuticals shares outstanding

The number of shares was Botanix Pharmaceuticals in 2023 — This indicates how many shares 1.154 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Botanix Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Botanix Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Botanix Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Botanix Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Botanix Pharmaceuticals Aktienanalyse

What does Botanix Pharmaceuticals do?

Botanix Pharmaceuticals Ltd is an Australian company specializing in the research and development of innovative therapies based on synthetic cannabinoids. The company was founded in 2014 by a team of experts and is headquartered in Perth, Western Australia. The history of Botanix Pharmaceuticals began with the discovery of the medical properties of cannabinoids derived from the hemp plant. Cannabinoids have a wide therapeutic potential, ranging from pain and inflammation relief to the treatment of seizure disorders and anxiety. Botanix Pharmaceuticals utilizes these properties to develop innovative product candidates that have high efficacy and tolerability. The business model of Botanix Pharmaceuticals is based on the concept of targeted treatment for diseases and conditions where traditional therapies are insufficient or cause unwanted side effects. The company develops and produces medications based on synthetic cannabinoids that target specific disease states and indications. Botanix Pharmaceuticals specializes in two areas. Firstly, it focuses on the development of topical products, such as ointments and creams, that are applied to the skin. These products are particularly effective in treating skin conditions such as acne or psoriasis. Secondly, the company is working on the development of medications for the treatment of internal conditions such as epilepsy or chronic obstructive pulmonary disease (COPD). In the field of topical products, Botanix Pharmaceuticals has already achieved significant success. The company has a promising pipeline of product candidates for various applications, including acne, psoriasis, atopic dermatitis, and bacterial infections. One promising drug candidate is BTX 1503, which was developed for the treatment of severe acne. It contains the synthetic cannabinoid BTX 1308, which possesses anti-inflammatory and antimicrobial properties. BTX 1503 has already demonstrated high efficacy and tolerability in clinical studies. In the field of internal conditions, Botanix Pharmaceuticals collaborates closely with leading institutions and research facilities to develop innovative therapies for seizure disorders and COPD. One promising product candidate is BTX 1801, which was developed for the treatment of severe epilepsy. BTX 1801 contains the synthetic cannabinoid BTX 1204, which has shown high efficacy and tolerability in the treatment of seizures. Botanix Pharmaceuticals is an innovative company that develops highly effective and tolerable medications based on synthetic cannabinoids. The company has already achieved remarkable success in a short period and has established itself as a leading player in the industry. With its pipeline of promising product candidates and its close collaboration with renowned research institutions, Botanix Pharmaceuticals is well-positioned to develop further innovative therapies in the future. Botanix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Botanix Pharmaceuticals's Shares Outstanding

Botanix Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Botanix Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Botanix Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Botanix Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Botanix Pharmaceuticals stock

How many stocks are there of Botanix Pharmaceuticals?

The current number of stocks of Botanix Pharmaceuticals is 1.5 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Botanix Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Botanix Pharmaceuticals evolved in recent years?

The number of shares of Botanix Pharmaceuticals has increased by 30.12% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Botanix Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Botanix Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Botanix Pharmaceuticals pay?

Over the past 12 months, Botanix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Botanix Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Botanix Pharmaceuticals?

The current dividend yield of Botanix Pharmaceuticals is .

When does Botanix Pharmaceuticals pay dividends?

Botanix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of April, October, April, November.

How secure is the dividend of Botanix Pharmaceuticals?

Botanix Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Botanix Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Botanix Pharmaceuticals located?

Botanix Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Botanix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Botanix Pharmaceuticals from 10/25/1996 amounting to 0.048 AUD, you needed to have the stock in your portfolio before the ex-date on 10/3/1996.

When did Botanix Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/25/1996.

What was the dividend of Botanix Pharmaceuticals in the year 2023?

In the year 2023, Botanix Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Botanix Pharmaceuticals pay out the dividend?

The dividends of Botanix Pharmaceuticals are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Botanix Pharmaceuticals

Our stock analysis for Botanix Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Botanix Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.